The innovations will open up the cut fruit market, cut food waste, unlock new export markets, and reduce shipping costs, claims Tropic.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its ...

The global Gene Therapy market, valued at US$7.21 billion in 2023, is forecasted to grow at a robust CAGR of 19.4%, reaching ...

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

2018 saw a breakthrough in the field of RNA interference (RNAi), when the US FDA approved the first drug using this gene-silencing mechanism. Five years and five more approved drugs later ...

Various gene silencing technologies like siRNA, miRNA, ribozymes, DNAzymes have shown promise as therapeutics agents against viral diseases. RNAi-based drugs against viruses such as ebola virus ...

The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered the most efficient gene silencing technology.

Using RNA to interfere with a gene’s expression ... that showed a single injection of divalent siRNA led to silencing of the gene that causes Huntington’s. This silencing lasted at least ...